Ceesay Abraham, CEO, made one open market sale of Pacira BioSciences ($PCRX) shares worth $64,005 on September 4, 2025, ranking 10,111th among insiders for sales volume. He conducted 24 open market sales of Rapport Therapeutics ($RAPP) shares totaling 3.5 million, with the latest on February 18, 2026, ranking 2,445th. Among 11,678 insiders with sales over the past year, the average is 8.6 million per person across about 6.4 transactions. Abraham recorded no open market purchases.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 18, 2026 | Rapport Therapeutics, Inc. | $RAPP | Ceesay Abraham | Chief Executive Officer | S | Common Stock | 2281 | $29.80 | 658,705.0000 | 47,661,138 | 0.35% | 0.00% |
| Feb. 18, 2026 | Rapport Therapeutics, Inc. | $RAPP | Ceesay Abraham | Chief Executive Officer | S | Common Stock | 2100 | $29.80 | 658,705.0000 | 47,661,138 | 0.32% | 0.00% |
| Feb. 18, 2026 | Rapport Therapeutics, Inc. | $RAPP | Ceesay Abraham | Chief Executive Officer | S | Common Stock | 2983 | $29.04 | 660,805.0000 | 47,661,138 | 0.45% | 0.01% |
| Feb. 18, 2026 | Rapport Therapeutics, Inc. | $RAPP | Ceesay Abraham | Chief Executive Officer | S | Common Stock | 3552 | $29.05 | 660,986.0000 | 47,661,138 | 0.53% | 0.01% |
| Feb. 2, 2026 | Rapport Therapeutics, Inc. | $RAPP | Ceesay Abraham | Chief Executive Officer | A | Stock Option (Right to Buy) | 428000 | $0.00 | 428,000.0000 | 47,661,138 | 9999.99% | 0.90% |
| Jan. 20, 2026 | Rapport Therapeutics, Inc. | $RAPP | Ceesay Abraham | Chief Executive Officer | S | Common Stock | 5083 | $26.11 | 669,621.0000 | 47,661,138 | 0.75% | 0.01% |
| Jan. 20, 2026 | Rapport Therapeutics, Inc. | $RAPP | Ceesay Abraham | Chief Executive Officer | S | Common Stock | 5833 | $26.12 | 669,621.0000 | 47,661,138 | 0.86% | 0.01% |
| Dec. 17, 2025 | Rapport Therapeutics, Inc. | $RAPP | Ceesay Abraham | Chief Executive Officer | S | Common Stock | 2792 | $30.04 | 681,137.0000 | 47,661,138 | 0.41% | 0.01% |
| Dec. 17, 2025 | Rapport Therapeutics, Inc. | $RAPP | Ceesay Abraham | Chief Executive Officer | S | Common Stock | 515 | $31.04 | 680,537.0000 | 47,661,138 | 0.08% | 0.00% |
| Dec. 17, 2025 | Rapport Therapeutics, Inc. | $RAPP | Ceesay Abraham | Chief Executive Officer | S | Common Stock | 2421 | $30.04 | 681,052.0000 | 47,661,138 | 0.35% | 0.01% |
| Dec. 17, 2025 | Rapport Therapeutics, Inc. | $RAPP | Ceesay Abraham | Chief Executive Officer | S | Common Stock | 2147 | $28.84 | 683,473.0000 | 47,661,138 | 0.31% | 0.00% |
| Dec. 17, 2025 | Rapport Therapeutics, Inc. | $RAPP | Ceesay Abraham | Chief Executive Officer | S | Common Stock | 600 | $31.04 | 680,537.0000 | 47,661,138 | 0.09% | 0.00% |
| Dec. 17, 2025 | Rapport Therapeutics, Inc. | $RAPP | Ceesay Abraham | Chief Executive Officer | S | Common Stock | 2441 | $28.84 | 683,929.0000 | 47,661,138 | 0.36% | 0.01% |
| Nov. 17, 2025 | Rapport Therapeutics, Inc. | $RAPP | Ceesay Abraham | Chief Executive Officer | S | Common Stock | 2777 | $24.92 | 694,509.0000 | 47,661,138 | 0.40% | 0.01% |
| Nov. 17, 2025 | Rapport Therapeutics, Inc. | $RAPP | Ceesay Abraham | Chief Executive Officer | S | Common Stock | 3056 | $25.43 | 691,453.0000 | 47,661,138 | 0.44% | 0.01% |
| Nov. 17, 2025 | Rapport Therapeutics, Inc. | $RAPP | Ceesay Abraham | Chief Executive Officer | S | Common Stock | 2242 | $24.91 | 694,294.0000 | 47,661,138 | 0.32% | 0.00% |
| Nov. 17, 2025 | Rapport Therapeutics, Inc. | $RAPP | Ceesay Abraham | Chief Executive Officer | S | Common Stock | 2841 | $25.44 | 691,453.0000 | 47,661,138 | 0.41% | 0.01% |
| Oct. 15, 2025 | Rapport Therapeutics, Inc. | $RAPP | Ceesay Abraham | Chief Executive Officer | S | Common Stock | 4647 | $25.72 | 703,555.0000 | 36,496,437 | 0.66% | 0.01% |
| Oct. 15, 2025 | Rapport Therapeutics, Inc. | $RAPP | Ceesay Abraham | Chief Executive Officer | S | Common Stock | 755 | $26.17 | 702,369.0000 | 36,496,437 | 0.11% | 0.00% |
| Oct. 15, 2025 | Rapport Therapeutics, Inc. | $RAPP | Ceesay Abraham | Chief Executive Officer | S | Common Stock | 4328 | $25.75 | 703,124.0000 | 36,496,437 | 0.61% | 0.01% |
| Oct. 15, 2025 | Rapport Therapeutics, Inc. | $RAPP | Ceesay Abraham | Chief Executive Officer | S | Common Stock | 1186 | $26.14 | 702,369.0000 | 36,496,437 | 0.17% | 0.00% |
| Sept. 17, 2025 | Rapport Therapeutics, Inc. | $RAPP | Ceesay Abraham | Chief Executive Officer | S | Common Stock | 39435 | $26.30 | 714,685.0000 | 36,496,437 | 5.23% | 0.11% |
| Sept. 17, 2025 | Rapport Therapeutics, Inc. | $RAPP | Ceesay Abraham | Chief Executive Officer | S | Common Stock | 700 | $27.04 | 713,285.0000 | 36,496,437 | 0.10% | 0.00% |
| Sept. 17, 2025 | Rapport Therapeutics, Inc. | $RAPP | Ceesay Abraham | Chief Executive Officer | S | Common Stock | 34885 | $26.30 | 713,985.0000 | 36,496,437 | 4.66% | 0.10% |
| Sept. 17, 2025 | Rapport Therapeutics, Inc. | $RAPP | Ceesay Abraham | Chief Executive Officer | S | Common Stock | 1400 | $26.87 | 713,285.0000 | 36,496,437 | 0.20% | 0.00% |
| Sept. 4, 2025 | Pacira BioSciences, Inc. | $PCRX | Ceesay Abraham | Director | S | Common Stock | 2354 | $27.19 | 9,039.0000 | 46,245,000 | 20.66% | 0.01% |
| June 11, 2025 | Pacira BioSciences, Inc. | $PCRX | Ceesay Abraham | Director | A | Stock Option (Right to Buy) | 11279 | $0.00 | 11,279.0000 | 46,245,000 | 9999.99% | 0.02% |
| June 11, 2025 | Pacira BioSciences, Inc. | $PCRX | Ceesay Abraham | Director | A | Common Stock | 6163 | $0.00 | 11,393.0000 | 46,245,000 | 117.84% | 0.01% |
| June 2, 2025 | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | $CRL | Ceesay Abraham | Director | A | Common Stock | 946 | $135.04 | 946.0000 | 51,201,000 | 9999.99% | 0.00% |
| June 2, 2025 | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | $CRL | Ceesay Abraham | Director | A | Stock Options (Right to Buy) | 2082 | $135.04 | 2,082.0000 | 51,201,000 | 9999.99% | 0.00% |
| Feb. 3, 2025 | Rapport Therapeutics, Inc. | $RAPP | Ceesay Abraham | Chief Executive Officer | A | Stock Option (Right to Buy) | 428000 | $0.00 | 428,000.0000 | 0 | 9999.99% | 0.00% |
| June 12, 2024 | Pacira BioSciences, Inc. | $PCRX | Ceesay Abraham | Director | A | Common Stock | 5230 | $0.00 | 5,230.0000 | 51,979,000 | 9999.99% | 0.01% |
| June 12, 2024 | Pacira BioSciences, Inc. | $PCRX | Ceesay Abraham | Director | A | Stock Option (Right to Buy) | 12179 | $0.00 | 12,179.0000 | 51,979,000 | 9999.99% | 0.02% |
| June 6, 2024 | Rapport Therapeutics, Inc. | $RAPP | Ceesay Abraham | Chief Executive Officer | A | Stock Option (Right to Buy) | 530647 | $0.00 | 530,647.0000 | 0 | 9999.99% | 0.00% |
| Oct. 6, 2023 | Pacira BioSciences, Inc. | $PCRX | Ceesay Abraham | Director | A | Stock Option (Right to Buy) | 30967 | $0.00 | 30,967.0000 | 46,538,000 | 9999.99% | 0.07% |